Press release
Macomics to Present at Upcoming Conferences, Q3 2022
Edinburgh and Cambridge, UK, 1 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
• Dr Luca Cassetta, co-founder and VP Immunology of Macomics will be attending the 2022 ISEH Annual meeting, Edinburgh, 1-4 September
o Speaking at Q&A session on transition from academia to start up, 2 September
• Dr Steve Myatt, CEO of Macomics, will be…
AMSBIO has published an interview with Professor Marius Wernig from Stanford University, Pathology Stem Cell Institute that discusses what could be the world’s first widely applicable curative treatment for Epidermolysis Bullosa (EB).
This rare genetic disease causes chronic and incredibly painful skin wounds that often lead to an aggressive form of skin cancer and eventual death.
While various cell-therapy approaches have been attempted, Professor Wernig and collaborators identified the need for induced pluripotent stem cells (iPSCs), and how they could become used to treat EB in a more…
The next wave of talent “…are looking for destination locations that align with the values and ethos of the company and often the physical structure that’s in to enable innovation is part of what attracts the best people” Tony Jones, One Nucleus.
Listen to the full podcast with Chris Walters, JLL’s Head of UK Life Sciences and Tony Jones, CEO of One Nucleus where they discussed the importance of destination locations for innovation in life sciences. They covered a range of topics affecting the life sciences sector in the UK including, how destination real estate locations can enable…
The world of life sciences is complex - add insurance requirements into the mix and it can become a very confusing place to be.
Having appropriate insurance and risk management solutions in place can be crucial for any life science business, whether your seeking initial funding, running clinical trials or taking a product to market.
There are many questions that arise – and myths that surround these topics. Here we share some of the most common myths that have been debunked by CFC Underwriting, a specialist insurance provider to the science and technology sectors.
With constant…
Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform
Cambridge, UK 16th August 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene synthesis platforms.
Evonetix’s proprietary process utilises a novel…
16th AUGUST 2022
Designed to efficiently induce differentiation in ES and iPS cells, AMSBIO has expanded its iMatrix series of recombinant laminin E8 fragments to now include isoforms LN-111 and LN-332.
This expanded range of laminin isoforms (LN-111, 332, 511, 411 and 221) now provides even greater flexibility and control when tailoring your substrate to the requirements of specific cultured cells.
Proven in many leading life science research labs - iMatrix is used as a substrate for culturing and maintaining cells, including Pluripotent Stem Cells and Mesenchymal Stem Cells, as well…
Cambridge UK: 11 August 2022
Partners& has become the latest partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
Hanna Beaumont FIRM, Client Partner – Science & Technology, Partners& commented ‘We are dedicated to enhancing the resilience of companies in the science and technology sectors. We do this by providing the risk management advice that will enable them to continue to develop innovative products, raise…
AMSBIO offers a range of lentivirus production services to provide tailor-made products to support your research.
Lentiviral vectors are a valuable tool for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo. Typically, production of custom lentiviral vectors is a laborious and challenging process, especially when high-titer lentiviral vectors are required. The custom lentiviral vector production service from AMSBO offers researchers a proven partner to avoid this bottleneck and speed up your research.
The AMSBIO custom lentivirus service…